Artelo Biosciences files provisional patent for ART27.13 obesity use after mouse study shows up to 40% weight loss with semaglutide
Bitget2026/09/23 11:33- Artelo Biosciences filed a provisional patent application covering ART27.13 for obesity as a standalone treatment or with GLP-1 drugs.
- Results were already presented from a nonclinical obese-mouse study, with additional findings disclosed following data released on Sept. 16, 2026.
- ART27.13 showed meaningful weight-loss activity alone, with stronger results when combined with semaglutide.
- The combination also improved metabolic markers and showed a bone-health signal not seen in other study groups.
- The move positions ART27.13 as a potential add-on to GLP-1 therapies, supported by an existing clinical dataset across multiple studies.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Similarweb names Digital Turbine executive Michael Akkerman as CEO effective Nov. 2, 2026
The number of initial unemployment claims in the US last week fell to 197,000, one of the lowest levels since 1969.
The US labor market demonstrates resilience, as initial jobless claims for the week ending September 19 fell to 197,000, the lowest level since July and one of the lowest readings since 1969. The four-week average also declined, indicating that high interest rates have yet to trigger large-scale layoffs. However, the market shows a structural feature of "low layoffs but uneven hiring," with job-seeking and job-hopping opportunities still limited.
Ripple CEO Brad Garlinghouse: ‘I Am Not An XRP Maximalist’
Sector Update: Energy Stocks Rise Premarket Thursday
Crypto prices
More
